PACKAGING OF HEPATITIS B SURFACE ANTIGEN VACCINE AND MORINGA OLEIFERA EXTRACT INTO CHITOSAN NANOPARTICLES

Journal Title: Asian Journal of Pharamceutical and Clinical Research - Year 2019, Vol 12, Issue 1

Abstract

Objective: Oftentimes, the recombinant antigen for the use of vaccines is less immunogenic than live attenuated or inactive vaccines. Hence, a potent adjuvant is needed to enhance the immune response. Moreover, the role of vector design is also important to facilitate the improvement of the immune response. The aim of this research was to develop hepatitis B surface antigen (HBsAg)-loaded nanoparticles and Moringa oleifera aqueous leaf extracts as an adjuvant using chitosan polymer. Methods: Chitosan nanoparticles were prepared by the ionic gelation method using sodium tripolyphosphate as the cross-linking agent. A system was composed of chitosan core in which HBsAg and M. oleifera extracts were incorporated. The concentration of HBsAg used in this combination was 10 μg/ml, and the concentrations of extracts were 10, 50, and 100 μg/ml, respectively. In this study, three types of nanoparticles were produced: HBsAg-loaded nanoparticles, M. oleifera-loaded nanoparticles, and combination of HBsAg–M. oleifera-loaded nanoparticles. The nanoparticles formed were characterized by the particle size, HBsAg entrapment efficiency using sodium dodecyl sulfate polyacrylamide gel electrophoresis, and the entrapment efficiency of extracts using the total flavonoid method. Results: The results showed that the particle size was between 111 and 245 nm. The entrapment efficiency of HBsAg in the separate formula was 79%, while that in the combined formula was approximately 96–98%. Furthermore, the entrapment efficiency of the extracts in the separate formula was around 64–91%, while that in the combined formula was 55–82.5%. Particularly, HBsAg–M. oleifera-loaded chitosan nanoparticles with the extract concentrations of 50 μg/ml showed the highest entrapment efficiencies of HBsAg and M. oleifera extracts of approximately 98 and 82.5%, respectively. Conclusion: Collectively, the system has been successfully developed, so it is then plausible to determine the function of the devices to enhance the immune response in the future.

Authors and Affiliations

Diky Mudhakir, Adik Ahmadi, Muhamad Insanu, Neny Nuraini

Keywords

Related Articles

LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM IN ADENOMYOSIS; PREDICTORS FOR RESPONSE AND CLINICAL OUTCOME

Objectives: The aim is to detect clinical and ultrasonographic characters that predict the response of adenomyosis to levonorgestrel-releasing intrauterine system (LNG-IUS) and to evaluate the clinical efficacy and the t...

EVALUATION AND COMPARISON OF CYTOTOXIC EFFECT OF VILAZODONE HYDROCHLORIDE WITH 5-FLUOROURACIL IN HT-29 BOWEL CANCER CELL LINE

Objectives: Vilazodone hydrochloride is a novel selective serotonin reuptake inhibitor (SSRI) used to treat major depressive disorders. There are only sparse data available to know about the SSRI’s and its association wi...

DESIGN AND SYNTHESIS OF NOVEL 4-(4-FLUORO-3-METHYLPHENYL)-6-(SUBSTITUTED ARYL)-1,6-DIHYDROPYRIMIDIN-2-OL DERIVATIVES AS POTENT ANTI-INFLAMMATORY AND ANALGESIC AGENTS

Objective: Pyrimidine heterocycles possessing hydroxy group has a unique place in medicinal chemistry and also plays a key role in biological processes. In the biological functions at cellular level pyrimidine plays impe...

CHEMICAL AND BIOLOGICAL STUDY OF EUGENIA STIPITATA MC VAUGH COLLECTED IN THE COLOMBIAN ANDEAN REGION

Objective: The main objective of this study is to evaluate the chemical and bioactive properties of Eugenia stipitata (Myrtaceae) fruit seeds collected in the Andean region of Colombia using an ethanolic extract, a dichl...

A CASE REPORT OF ZIDOVUDINE-INDUCED THUMBNAILS HYPERPIGMENTATION IN AN HIV POSITIVE PATIENT WITH SECONDARY HERPES ZOSTER OPHTHALMICUS INFECTION

Zidovudine is one of the first-line antiretroviral therapy regimen drug used to treat human immunodeficiency virus infected patients. Nail pigmentation associated with zidovudine therapy is seen in adults and children’s,...

Download PDF file
  • EP ID EP607159
  • DOI 10.22159/ajpcr.2019.v12i1.15386
  • Views 124
  • Downloads 0

How To Cite

Diky Mudhakir, Adik Ahmadi, Muhamad Insanu, Neny Nuraini (2019). PACKAGING OF HEPATITIS B SURFACE ANTIGEN VACCINE AND MORINGA OLEIFERA EXTRACT INTO CHITOSAN NANOPARTICLES. Asian Journal of Pharamceutical and Clinical Research, 12(1), 346-350. https://europub.co.uk./articles/-A-607159